Clinical Scorecard: Development and Validation of a Nomogram Model for Prognostic Assessment in Primary Cervical Squamous Cell Carcinoma with Serum SCC Antigen Levels ≥10 ng/mL Using Inflammatory Biomarkers and Clinical Variables

At a Glance

Key Highlights

• Cervical cancer is the most prevalent malignancy of the female reproductive system.
• Pretreatment SCC-Ag levels ≥10 ng/mL indicate increased tumor aggressiveness and higher recurrence risk.
• Inflammatory markers and hematological parameters are linked to survival outcomes.
• A novel prognostic model was developed for patients with high SCC-Ag levels.
• The model aims to improve individualized treatment strategies.

Guideline-Based Recommendations

Diagnosis

• Confirm cervical squamous cell carcinoma pathologically.
• Monitor serum SCC-Ag levels as a prognostic indicator.

Management

• Utilize radiotherapy regimens including external beam pelvic radiotherapy and intracavitary brachytherapy.

Monitoring & Follow-up

• Dynamic monitoring of serum SCC-Ag levels to assess treatment response and recurrence risk.

Risks

• Patients with SCC-Ag ≥10 ng/mL have a higher likelihood of treatment resistance and disease recurrence.

Patient & Prescribing Data

355 patients with primary cervical cancer treated between January 2020 and December 2023.

Radiotherapy regimens included advanced techniques such as VMAT, IMRT, and TOMO.

Clinical Best Practices

• Integrate inflammatory markers and blood parameters into prognostic models for cervical cancer.
• Tailor treatment strategies based on individualized risk assessments.

References

• Cervical Cancer Overview
• SCC-Ag and Prognosis
• Inflammatory Markers in Cancer